Emerging Credit Rating Limited (ECRL) has assigned BBB (Pronounced as Triple B) long term credit rating and ST-3 short term credit rating to Indo-Bangla Pharmaceuticals Limited. The outlook of the rating is Stable. The rating is based on the audited financial statements for FY2019-FY2021 and other relevant qualitative and quantitative information up to the date of rating.